Professor Wang Weiqing and her team won the Second Prize of 2017 National Science and Technology Progress Awards

The 2017 national science and technology Progress awards conference was held in Beijing on the morning of January 8. The national science and technology awards conference selected 280 items in total, including 9 personal awards and 271 projects. The project “new discovery of endocrine tumor pathogenesis and establishment and application of clinical diagnosis and treatment technology” led by Professor Wang Weiqingfrom Ruijin Hospital won the second prize of national science and technology progress award.

The project lasted for 12 years, stuck to the clinical demand, and established various endocrine tumor 34 clinical diagnosis of new technology, capability assessment and tumor location precision hormones secretionby systemic screening optimization. Nine new genes and molecular markers were found, and molecular markers of endocrine tumor and malignant tumor were proposed. They created 4 new treatments, developed expert consensus and rewrite international guidelines; It reveals that abnormal glucose metabolism increases the risk of cancer. The research results are in the leading position in China and at the advanced international level. Some research was published in the journal Science, JAMA and other international authorities. The paper published in Science received peercomments and those published in the Lancet, Nature Rev Endocrinologywere praised highly of these authoritative magazines.They were named “2014 China‘s most influential international academic papers”. They did keynote report at the 15th Annual R Symposium Levine of the United States to promote the study on the etiology and proliferation of islet cell tumors. At the same time, JAMA published a statement by the chairman of the international diabetes federation education, which highly valued the study as an important public health warning. The project was granted 11 national patents. The group entrusted by the Chinese medical association endocrinology branch, and carried out a number of endocrine tumor expert consensus and clinical pathway, popularized and applied research more than 30 hospitals across the country, which obtained good effects. The results of the project have been cited by international authoritative academic institutions as an important evidence-based medical evidence for first-line treatment programs. The project based on the “Shanghai key laboratory of endocrine tumor” has become the first domestic endocrine clinical laboratory certified by the CAP, and successfully passed the review twice. It greatly improved the diagnosis and treatment of endocrine tumors in our country with international influence.